Skip to Main Content

The (POGO) Blog

October 10, 2017

By Christine Ostrosky

IG Calls for Detailed Reporting on Medical Device Failures



Emergency room A new report from a federal watchdog calls on the government to require hospitals to provide more detailed reporting on medical device problems to the Centers for Medicare and Medicaid Services (CMS). Better reporting could help the government identify mal

Continue Reading IG Calls for Detailed Reporting on Medical Device Failures

Topics: Public Health and Science

August 17, 2017

By Laura Peterson

Lawmakers Question Interior Secretary Over Whistleblower Reassignment



Joel Clement Members of Congress are supporting a Department of Interior executive who says management retaliated against him because he disclosed how climate change is putting Alaskan coastal communities at risk.

Continue Reading Lawmakers Question Interior Secretary Over Whistleblower Reassignment

Topics: Whistleblower Protections, Energy and Natural Resources, Public Health and Science

April 3, 2017

By David S. Hilzenrath

Questions for Trump’s FDA Nominee



Scott Gottlieb President Donald Trump’s nominee to head the Food and Drug Administration has deep roots in the pharmaceutical industry he would oversee.

Continue Reading Questions for Trump’s FDA Nominee

Topics: Public Health and Science

March 28, 2017

By Ari Goldberg

POGO's 2017 Baker’s Dozen Wishlist for Congress



Aerial U.S. Capitol Building The Project On Government Oversight (POGO) has unveiled its biennial list of 13 policy areas ripe for Congressional action. It includes recommendations for legislative fixes to make the federal government more transparent, accountable, and ethical.

Continue Reading POGO's 2017 Baker’s Dozen Wishlist for Congress

Topics: Government Accountability, Open Government, Whistleblower Protections, Energy and Natural Resources, National Security, Public Health and Science, Contract Oversight

March 3, 2017

By David S. Hilzenrath

Trump’s Dangerous Prescription for the FDA



President Trump addressing a joint session of Congress, with VP Mike Pence and Rep. Paul Ryan seated behind him, clapping. President Donald Trump called the FDA drug approval process slow and burdensome, but the evidence he cited could point to the opposite conclusion. Slashing regulatory restraints as he proposed could pose medical and financial hazards.

Continue Reading Trump’s Dangerous Prescription for the FDA

Topics: Government Accountability, Open Government, Public Health and Science

Items 1 - 5 of 52  12345678910Next

Browse POGOBlog by Topic

POGO on Facebook